ClinicalTrials.gg

Muscular Dystrophy, Duchenne clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 482 studies for Muscular Dystrophy, Duchenne across more than 10 countries. 107 are recruiting or about to start. 449 of them are mainly about Muscular Dystrophy, Duchenne (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
237
Recruiting
65
Terminated
53
Active, not recruiting
38
Status unknown
34
Not yet recruiting
21

Phase

Phase 2
142
Phase 1
93
Phase 3
59
Phase 4
10
Early Phase 1
9

Where

United States
233
United Kingdom
84
Italy
82
Turkey
68
France
66
Canada
66

Who develops what

Add Muscular Dystrophy, Duchenne to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 14 companies, 15 with this as their studies’ main aim; 3 with a live phase 3 study; 6 primary completions in the next 12 months. Compare BioMarin Pharmaceutical, Grünenthal and Italfarmaco here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SirolimusRecent, limited
Evidence
  • NCT07542314 · Sarepta Therapeutics, Inc. · Phase 4 · live · background · “Sirolimus” · registered Apr 2026
Pfizer39% of its industry studiesUS: off-patent, 10 generics marketedEU: Pfizer (EMA 2001) + 1 other11 study
GlucocorticoidsRecent, limited
Evidence
  • NCT07542314 · Sarepta Therapeutics, Inc. · Phase 4 · live · background · “Glucocorticoids” · registered Apr 2026
Staidson (Beijing) Biopharmaceuticals Co., Ltd33% of its industry studies11 study
Anti-Bacterial AgentsRecent, limited
Evidence
  • NCT07542314 · Sarepta Therapeutics, Inc. · Phase 4 · live · background · “Antibiotics” · registered Apr 2026
—11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
SGT-003☆ Track1 live phase-3 study: NCT07160634Solid Biosciences Inc.
delpacibart zotadirsen☆ Track1 live phase-3 study: NCT07587242Novartis
zeleciment rostudirsen☆ Track1 live phase-3 study: NCT07608432Dyne Therapeutics

The 3 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 Feb 2027 est.brogidirsen · NS Pharma, Inc. · Phase 2 main aimNCT05996003 NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) — primary endpoint: Adverse Event and Adverse Drug Reaction · 20 enrolled
  • 31 Mar 2027 est.SAT-3247 · Satellos Bioscience, Inc. · Phase 2 main aimNCT07287189 Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients — primary endpoint: Safety of SAT-3247 · 51 enrolled
  • 14 Apr 2027 est.BMN 351 · BioMarin Pharmaceutical · Phase 2 main aimNCT06280209 A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy — primary endpoint: To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters). · 18 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Muscular Dystrophy, Duchenne studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here HDAC inhibitors 3 open · PDE5 inhibitors 1 open · Corticosteroids 1 open · Beta blockers 1 open · Mineralocorticoid receptor antagonists (MRAs) 3

Coming up

40studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger. 58 (89%) take children under 18. 1 (2%) are for women only and 42 (65%) for men only; 11 (17%) take healthy volunteers.

Recruiting studies that take each age, of 65
AgeWomenMen
1018 (28%)45 (69%)
1821 (32%)45 (69%)
3020 (31%)36 (55%)
4019 (29%)34 (52%)
5019 (29%)33 (51%)
6519 (29%)32 (49%)
7518 (28%)31 (48%)
8517 (26%)30 (46%)

Across all 482 studies, recruiting or not: 66% stop at 75 or younger and 65% at 65; 90% take children; 1% are for women only and 76% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Muscular Dystrophy, Duchenne studies take

Of 47 phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 119 mo11–35 · 28 studies——
Phase 1/250 mo24–63 · 23 studies——
Phase 231 mo20–42 · 47 studies31 mo20–42 · 40 studies—
Phase 354 mo38–73 · 26 studies——
Interventional, no phase20 mo10–44 · 47 studies—19 mo10–44 · 45 studies
Observational40 mo12–120 · 63 studies—37 mo11–120 · 52 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 482. Browse all 482 → or search them.